Smo inhibitors improve therapeutic efficacy by sensitizing dormant LSCs to chemotherapy and overcoming microenvironment-induced chemoresistance, and targeting Gli-1 also suppresses proliferation and enhances chemosensitivity in AML cells and progenitor cells [65–67]. Here, SMO is linked to acute myeloid leukemia.